Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 3:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 1,356 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Resolution Clear all
Completed Phase 4 Interventional Results available

Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis

NCT04485546
View directory record Official record
Conditions
Neurotrophic Keratitis
Interventions
cenegermin-bkbj
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
San Diego, California • Edgewood, Kentucky • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 28, 2026, 3:40 AM EDT
Completed Not applicable Interventional

Study of Low Adherent Dressing Versus the Standard of Care for the Management of Skin Grafts Over Thermal Burns

NCT01654094
View directory record Official record
Conditions
Burns, Skin Burn Requiring Skin Graft
Interventions
P6 Low Adherent Dressing, Standard of Care (SOC)
Device · Other
Lead sponsor
Milliken Healthcare Products, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
4
States / cities
Gainesville, Florida • Chapel Hill, North Carolina • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 28, 2026, 3:40 AM EDT
Completed Early Phase 1 Interventional

Chlorine Dioxide Versus Saline for Wound Irrigation

NCT01341041
View directory record Official record
Conditions
Wound - in Medical Care
Interventions
chlorine dioxide, saline
Biological
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 25, 2011 · Synced Oct 28, 2026, 3:40 AM EDT
Not yet recruiting Not applicable Interventional

Study of a 1-Millimeter Resolution Clinical Positron Emission Tomography (PET) System in Head and Neck Cancer Imaging

NCT04662554
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
1-mm Resolution Clinical PET camera
Device
Lead sponsor
Stanford University
Other
Eligibility
19 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 28, 2026, 3:40 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness

NCT01959230
View directory record Official record
Conditions
Hyperemia
Interventions
Brimonidine Tartrate, Vehicle, Sodium Fluorescein, Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 28, 2026, 3:40 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of an Investigational Multi-Purpose Solution (MPS)

NCT00961051
View directory record Official record
Conditions
Study Focus is Healthy Contact Lens Wearers
Interventions
Investigational MPS, Opti-Free
Device
Lead sponsor
Abbott Medical Optics
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
9
States / cities
San Diego, California • Waipahu, Hawaii • Warrensburg, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Oct 28, 2026, 3:40 AM EDT
Recruiting Phase 2 Interventional

Autologous Serum Tears With Hyaluronate vs Balanced Salt Solution for Moderate-to-Severe Dry Eye

NCT07413172
View directory record Official record
Conditions
Dry Eye, Eye Diseases, Eyes Dry Chronic
Interventions
Autologous Serum Tears (50% Autologous Serum Tears + 0.2% Sodium Hyaluronate), Biological - Autologous Serum Tears (50% Autologous Serum Tears + Balanced Saline Solution (BSS), Standard of Care (SOC) Treatment
Biological · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 28, 2026, 3:40 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model

NCT01134328
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
AC-150 Combo, AC-150A 0.1%, AC-150B 0.005%, Vehicle
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Oct 28, 2026, 3:40 AM EDT
Completed Not applicable Interventional Results available

Complex Sleep Apnea Syndrome (CompSAS) Resolution Study

NCT00915499
View directory record Official record
Conditions
Complex Sleep Apnea Syndrome
Interventions
VPAP Adapt SV
Device
Lead sponsor
ResMed
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
6
States / cities
Phoenix, Arizona • Chicago, Illinois • Skokie, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 28, 2026, 3:40 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease

NCT01126437
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium 18 mcg, tiotropium 1.25 mcg (2 actuations/day), tiotropium 2.5 mcg (2 actuations/day)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
17,183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
303
States / cities
Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 243 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2014 · Synced Oct 28, 2026, 3:40 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus

NCT01643226
View directory record Official record
Conditions
Keratoconus
Interventions
riboflavin solution, placebo solution, KXL System
Drug · Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
12 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
8
States / cities
San Diego, California • Indianapolis, Indiana • Overland Park, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 28, 2026, 3:40 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.

NCT03186378
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
VP-102 with applicator
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
2 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Oct 28, 2026, 3:40 AM EDT
Completed No phase listed Observational

Single Dose Pharmacokinetics and Pharmacodynamics of Bupivacaine Following Transversus Abdominis Plane (TAP) Block in Neonates

NCT01557985
View directory record Official record
Conditions
Postoperative Pain
Interventions
Bupivacaine
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Up to 28 Days
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 28, 2026, 3:40 AM EDT
Completed Phase 1Phase 2 Interventional

Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma

NCT00753168
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
OT-730 ophthalmic solution, timolol maleate ophthalmic solution, OT-730 placebo
Drug
Lead sponsor
Othera Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
5
States / cities
Artesia, California • Roswell, Georgia • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2009 · Synced Oct 28, 2026, 3:40 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium

NCT03049852
View directory record Official record
Conditions
Pterygium
Interventions
CBT-001 single dose, Vehicle, CBT-001 Multi-dose
Drug
Lead sponsor
Cloudbreak Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Laguna Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 28, 2026, 3:40 AM EDT
Completed Phase 3 Interventional Results available

Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

NCT02207491
View directory record Official record
Conditions
Ocular Hypertension, Open-angle Glaucoma
Interventions
Timolol maleate Ophthalmic Solution 0.5% BID, AR-13324 Ophthalmic Solution 0.02%, Placebo
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 28, 2026, 3:40 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

NCT00650338
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
DE-104 ophthalmic solution, low concentration, DE-104 ophthalmic solution, medium concentration, DE-104 ophthalmic solution, high concentration, Placebo, 0.005% latanoprost
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
14
States / cities
Artesia, California • Los Angeles, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2011 · Synced Oct 28, 2026, 3:40 AM EDT
Completed No phase listed Observational Results available

Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery

NCT01344226
View directory record Official record
Conditions
Pseudophakia, Inflammation
Interventions
loteprednol 0.5% ophthalmic solution
Drug
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Independence, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Oct 28, 2026, 3:40 AM EDT
Terminated No phase listed Observational

High Resolution 3D Diffusion-weighted Breast MRI

NCT01315106
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer
Interventions
Magnetic Resonance Image Scanner
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 28, 2026, 3:40 AM EDT
Completed Phase 2 Interventional Results available

Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT03118765
View directory record Official record
Conditions
Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Interventions
GSP304 (tiotropium bromide) Inhalation Solution, GSP304 Placebo Inhalation Solution, Spiriva® Respimat® inhalation spray
Drug
Lead sponsor
Glenmark Specialty S.A.
Industry
Eligibility
40 Years to 85 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
25
States / cities
Andalusia, Alabama • Phoenix, Arizona • Tempe, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 28, 2026, 3:40 AM EDT
Active, not recruiting Phase 4 Interventional

VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease

NCT06249165
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 28, 2026, 3:40 AM EDT
Completed Phase 3 Interventional Results available

OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis

NCT02054156
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
azithromycin, placebo, Tobramycin solution for inhalation
Drug
Lead sponsor
Bonnie Ramsey
Other
Eligibility
6 Months to 18 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
45
States / cities
Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 28, 2026, 3:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study of TRN-157 in Healthy Subjects

NCT02133339
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
TRN-157, Placebo
Drug
Lead sponsor
Theron Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 28, 2026, 3:40 AM EDT
Not listed Phase 1 Interventional

Imaging Trial of the Distribution of Topical Gel in the Human Vagina: Enhanced MRI Techniques to Increase Resolution

NCT00260767
View directory record Official record
Conditions
HIV
Interventions
HEC placebo gel
Drug
Lead sponsor
Biosyn
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2005 · Synced Oct 28, 2026, 3:40 AM EDT